IDH Inhibitors in the Treatment of Low-Grade Gliomas
Panelists discuss how IDH inhibitors such as ivosidenib could potentially reshape the treatment approach for low-grade gliomas, while also exploring what further clinical evidence would be necessary to confidently integrate these novel agents into standard care protocols.
EP: 1.Real-World Clinical Practice: Challenges With Glioma Management
EP: 2.Treatment Approaches for Patients With Oligodendrogliomas and Grade 2 Gliomas
EP: 3.CATNON Trial: Concurrent Versus Adjuvant Temozolomide in Treating WHO Grade 3 Astrocytomas Without 1p/19q Codeletion
Now Viewing
EP: 4.IDH Inhibitors in the Treatment of Low-Grade Gliomas
EP: 5.INDIGO Trial: Examining IDH-Mutant Low-Grad Gliomas
EP: 6.Closing Thoughts and Unmet Needs in Glioma Treatment
- Discuss the potential impact on IDH inhibitors like ivosidenib on the treatment landscape of low-grade gliomas
- What additional data would be relevant to incorporating these agents into clinical practice?
Related Content
